165 related articles for article (PubMed ID: 3966729)
21. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
Blickle JF; Brogard JM
Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
[No Abstract] [Full Text] [Related]
22. [Safety is the issue again].
Overbeck P
MMW Fortschr Med; 2013 Oct; 155(17):26. PubMed ID: 24340377
[No Abstract] [Full Text] [Related]
23. [40 years of using sulfonylurea derivatives for treatment of diabetes].
Sieradzki J
Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
[TBL] [Abstract][Full Text] [Related]
24. Sulphonylurea dose-response relationships: relation to clinical practice.
Lindblad U; Melander A
Diabetes Obes Metab; 2000 Jan; 2(1):25-31. PubMed ID: 11220350
[No Abstract] [Full Text] [Related]
25. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
26. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
27. Update on oral hypoglycemics (continuing education credit).
White JR
J Pract Nurs; 1994 Mar; 44(1):24-31; quiz 31-3. PubMed ID: 8158562
[No Abstract] [Full Text] [Related]
28. Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Sehra D; Sehra S
Recent Adv Cardiovasc Drug Discov; 2015; 10(1):4-9. PubMed ID: 26767545
[TBL] [Abstract][Full Text] [Related]
29. A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.
Riddle MC
Diabetes Care; 2019 Dec; 42(12):2161-2163. PubMed ID: 31748210
[No Abstract] [Full Text] [Related]
30. [Sulfonylureas].
Kobayashi K; Shimano H
Nihon Rinsho; 2012 May; 70 Suppl 3():602-7. PubMed ID: 22768585
[No Abstract] [Full Text] [Related]
31. [Not Available].
Viardot A
Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
[No Abstract] [Full Text] [Related]
32. If not sulfonylureas, then what?
Leibovitch ER
Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239
[No Abstract] [Full Text] [Related]
33. Failure of sulfonylureas in type 2 diabetes.
Yildiz BO; Gürlek A
Horm Metab Res; 1999 Apr; 31(4):293-4. PubMed ID: 10333089
[No Abstract] [Full Text] [Related]
34. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion.
Adachi H; Yanai H
Diabetes Metab; 2015 Apr; 41(2):176-7. PubMed ID: 25559655
[No Abstract] [Full Text] [Related]
35. Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.
Halimi S
Diabetes Metab; 2015 Apr; 41(2):105-6. PubMed ID: 25824635
[No Abstract] [Full Text] [Related]
36. Treating type 2 diabetes: targeting the many causative factors.
Sutherland JE; Hoehns JD
J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
[No Abstract] [Full Text] [Related]
37. Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
Genere N; Montori VM
Ann Intern Med; 2018 Jan; 168(2):JC8. PubMed ID: 29335720
[No Abstract] [Full Text] [Related]
38. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride.
Noakes R
Australas J Dermatol; 2003 Nov; 44(4):302-3. PubMed ID: 14616504
[No Abstract] [Full Text] [Related]
39. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
40. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
Heine RJ
Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
